 |
 Deborah joined SR One in 2005, is based in the UK and leads SR One’s activities in Europe. Deborah is a member of the Board of Directors of Addex Pharmaceuticals SA, PharmaKodex and Syntaxin and is an observer on the boards of 7TM and Resistentia Pharmaceuticals AB. Prior to SR One, Deborah was part of GSK's Worldwide Business Development team where she was responsible for sourcing and evaluating in-licensing opportunities in the Psychiatry, Neurology and Gastrointestinal therapeutic areas. During her time with Business Development Deborah led due diligence teams associated with successful in-licensing of preclinical and marketed products as well as a multiple-asset research and development collaboration. Prior to that Deborah held positions of increasing responsibility within SmithKline Beecham's development organisation covering clinical development, medical affairs, medical communications, medical marketing and business development support. She holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College. |
2008 SR One Ltd